Crescent Biopharma CBIO
NASDAQ CBIO
$13.17 +0.10 (+0.77%)
At close: Oct 21, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) Restructuring Costs (2024)

Updated

Crescent Biopharma (CBIO) recorded Restructuring Costs of $2.02 million in Q4 2024, down 63.4% from the prior quarter.

Analysis

Crescent Biopharma (CBIO) Restructuring Costs (2024) Analysis & Trends

For FY2024, Crescent Biopharma reported Restructuring Costs of $7.53 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Crescent Biopharma 401.19 Mn -306.10 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 2.02 Mn
Sep 30, 2024 5.51 Mn
API Access

Crescent Biopharma Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=CBIO&period=max&api_key=YOUR_API_KEY